Stryker, Abbott among Overweight ideas as Barclays turns bullish on MedTech
Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.
How this was made
The 30-second read
Why it matters
The new ratings and targets provide fresh actionable insight, likely prompting reallocation into the highlighted stocks.
Market read
First‑report analyst upgrade across a broad MedTech set, offering new price targets and sector optimism.
What to watch
Potential regulatory or reimbursement challenges could limit upside despite analyst optimism.
Background
Barclays initiated coverage of 26 MedTech companies, assigning Overweight ratings and new price targets across large‑cap and SMID‑cap names.
Ticker impact
Barclays named Stryker as an Overweight large‑cap MedTech idea with a $375 price target.
potential upside as investors price in the new target
Overweight rating and $375 target suggest strong buy pressure.
Barclays listed Abbott Laboratories as Overweight with a $120 price target.
likely upward pressure from the new target
Overweight rating signals confidence in future performance.
Barclays named Edwards Lifesciences as a top large‑cap Overweight idea with a $110 price target.
upside potential as market absorbs the target
High target relative to current price implies upside.
Barclays listed GE Healthcare as Overweight with a $85 price target.
possible upward move toward the target
Overweight status signals favorable outlook.
Barclays named Intuitive Surgical as Overweight with a $485 price target.
upward pressure as investors target the new level
High target suggests strong upside potential.
Barclays listed Beta Bionics as a top SMID‑cap Overweight idea with a $30 price target.
potential upside toward the target
Overweight rating signals confidence in growth.
Barclays listed LivaNova as Overweight with a $105 price target.
potential upside as market prices the target
Overweight rating indicates positive outlook.
Barclays named Axogen as an Overweight SMID‑cap idea with a $55 price target.
upward pressure toward the target
Target suggests upside potential.
Market effects
Broadly raises optimism for the MedTech sector, potentially lifting peers.
U.S. large‑cap and SMID‑cap MedTech stocks may see buying pressure.
May influence global medical device investors tracking U.S. exposure.
Counterpoint
Some investors may view the overweight ratings as premature given sector headwinds.
Key entities
- analyst_firmBarclays
Investment bank providing the Overweight ratings and price targets.
- analystChristopher Pasquale
Lead analyst for the MedTech coverage.
